{"entity":{"id":"scott-antonia","kind":"person","name":"Scott J. Antonia","aka":[],"tldr":"Led PACIFIC, which made a year of durvalumab after chemoradiation the standard for stage III lung cancer.","summary":"Scott Antonia was principal investigator of PACIFIC, the trial showing consolidation durvalumab after chemoradiotherapy improves progression-free and overall survival in unresectable stage III NSCLC, the first curative-intent immunotherapy result in lung cancer. He also led early nivolumab work in small-cell lung cancer (CheckMate 032). He now directs immunotherapy and cell therapy programmes at Duke.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Antonia%20SJ%5BAuthor%5D%20durvalumab%20PACIFIC"}],"tags":["lung","immunotherapy","stage-iii"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1"],"drugs":["durvalumab","nivolumab"],"companies":[],"institutions":["duke-cancer-institute"],"pathways":[],"terms":[],"trials":["pacific"],"people":[],"bottlenecks":[],"keyPapers":["paper-pacific-nejm-2017"],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Center for Cancer Immunotherapy, Duke Cancer Institute","institutionId":"duke-cancer-institute","specialisms":["Lung cancer immunotherapy","Stage III NSCLC","Tumour immunology","Cell therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Antonia%20SJ%5BAuthor%5D%20durvalumab%20PACIFIC"}],"papers":[{"title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer (PACIFIC)","journal":"NEJM","year":2017,"doi":"10.1056/NEJMoa1709937"},{"title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1809697"}],"orcid":"0000-0002-0029-9685"},"route":"/people/scott-antonia/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"duke-cancer-institute","kind":"institution","name":"Duke Cancer Institute","route":"/institutions/duke-cancer-institute/"}],"trial":[{"id":"pacific","kind":"trial","name":"PACIFIC","route":"/trials/pacific/"}],"paper":[{"id":"paper-spigel-pacific-five-year-survival-jco-2022","kind":"paper","name":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","route":"/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/"},{"id":"paper-pacific-nejm-2017","kind":"paper","name":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer","route":"/key-papers/paper-pacific-nejm-2017/"}]}}